AR102412A1 - Composiciones y métodos para el tratamiento con hemopexina - Google Patents
Composiciones y métodos para el tratamiento con hemopexinaInfo
- Publication number
- AR102412A1 AR102412A1 ARP150103147A ARP150103147A AR102412A1 AR 102412 A1 AR102412 A1 AR 102412A1 AR P150103147 A ARP150103147 A AR P150103147A AR P150103147 A ARP150103147 A AR P150103147A AR 102412 A1 AR102412 A1 AR 102412A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- compositions
- treatment
- hemopexine
- glycans
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000013271 Hemopexin Human genes 0.000 abstract 3
- 108010026027 Hemopexin Proteins 0.000 abstract 3
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 abstract 2
- 230000007935 neutral effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000007850 fluorescent dye Substances 0.000 abstract 1
- 150000003278 haem Chemical class 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 230000009450 sialylation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Composiciones y métodos para tratamientos terapéuticos que emplean moléculas de hemopexina recombinantes que presentan una sialilación suficiente y/o ausencia de glicanos neutros para permitir una circulación suficiente como para eliminar el hemo libre de un organismo biológico. En otras formas de realización, se provee una molécula de hemopexina recombinante para tratamientos terapéuticos que presenta un porcentaje de glicanos neutros a glicanos totales en un rango de entre aproximadamente un 2 y aproximadamente un 30 por ciento medido por HPLC después de marcarla con una sonda fluorescente de ácido 2-aminobenzoico. También se describen métodos de tratamiento y elaboración de una molécula de hemopexina recombinante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057613P | 2014-09-30 | 2014-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102412A1 true AR102412A1 (es) | 2017-03-01 |
Family
ID=55631377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103147A AR102412A1 (es) | 2014-09-30 | 2015-09-30 | Composiciones y métodos para el tratamiento con hemopexina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170218035A1 (es) |
| EP (1) | EP3209131A4 (es) |
| JP (1) | JP2017531643A (es) |
| CN (1) | CN106686982A (es) |
| AR (1) | AR102412A1 (es) |
| CA (1) | CA2962896A1 (es) |
| TW (1) | TW201629215A (es) |
| WO (1) | WO2016054072A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272167B2 (en) | 2017-08-08 | 2024-02-01 | Csl Behring Ag | Hemopexin formulations |
| US12239621B2 (en) | 2021-03-12 | 2025-03-04 | Niigata University | Prevention of kidney injury induced by hemolytic reaction |
| WO2025168750A1 (en) | 2024-02-09 | 2025-08-14 | Csl Behring Ag | Haptoglobin for use in treating traumatic brain injury (tbi) |
| WO2025257801A1 (en) * | 2024-06-13 | 2025-12-18 | CSL Innovation Pty Ltd | Heme-binding protein for the treatment of ischemia-reperfusion injury (iri) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2104610T3 (es) * | 1989-09-05 | 1997-10-16 | Biotech Australia Pty Ltd | Proceso para la preparacion de pai-2. |
| DK1342729T3 (da) * | 1997-07-09 | 2006-07-31 | Euroscreen Sa | Antistoffer og antisense-molekyler for G-koblet receptor der udviser selektiv affinitet for ATP |
| EP0984062A1 (en) * | 1998-09-04 | 2000-03-08 | Cytos Biotechnology AG | Production of human erythropoietin |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| PL1945665T3 (pl) * | 2005-10-21 | 2012-02-29 | Genzyme Corp | Leki oparte na przeciwciałach z ulepszoną aktywnością adcc |
| WO2012050874A2 (en) * | 2010-09-28 | 2012-04-19 | Soares Miguel P | Targeting heme for the treatment of immune mediated inflammatory diseases |
| PL3572090T3 (pl) * | 2012-12-24 | 2023-04-11 | Coagulant Therapeutics Corporation | Polipeptydy czynnika vii o krótkim działaniu |
-
2015
- 2015-09-25 TW TW104131703A patent/TW201629215A/zh unknown
- 2015-09-29 CN CN201580053165.8A patent/CN106686982A/zh active Pending
- 2015-09-29 US US15/515,304 patent/US20170218035A1/en not_active Abandoned
- 2015-09-29 WO PCT/US2015/052990 patent/WO2016054072A1/en not_active Ceased
- 2015-09-29 JP JP2017517799A patent/JP2017531643A/ja active Pending
- 2015-09-29 CA CA2962896A patent/CA2962896A1/en not_active Abandoned
- 2015-09-29 EP EP15847795.0A patent/EP3209131A4/en not_active Withdrawn
- 2015-09-30 AR ARP150103147A patent/AR102412A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201629215A (zh) | 2016-08-16 |
| CA2962896A1 (en) | 2016-04-07 |
| WO2016054072A1 (en) | 2016-04-07 |
| JP2017531643A (ja) | 2017-10-26 |
| CN106686982A (zh) | 2017-05-17 |
| EP3209131A4 (en) | 2018-03-21 |
| US20170218035A1 (en) | 2017-08-03 |
| EP3209131A1 (en) | 2017-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| CO2017000552A2 (es) | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70 | |
| CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| AR105600A1 (es) | Anticuerpos contra la angiopoyetina implicada en metabolismo de los triglicéridos (anti-angptl8) y usos de los mismos | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MX388380B (es) | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. | |
| BR112017012377A2 (pt) | conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula | |
| MX2017004708A (es) | Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control. | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| MX377089B (es) | Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral. | |
| MX2019009952A (es) | Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |